Form 4: Turn Therapeutics CFO Buys 2,500 Shares

Turn Therapeutics' Interim CFO, Zuraiz Chaudhary, purchased 2,500 shares of common stock at a weighted average price of $3.62.

Summary

• Zuraiz Chaudhary, the Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer of Turn Therapeutics Inc. (TTRX), acquired 2,500 shares of common stock.
• The transaction occurred on November 17, 2025, at a weighted average price of $3.62 per share.
• The shares were purchased in multiple transactions with prices ranging from $3.50 to $3.69.
• Following this acquisition, Chaudhary beneficially owns 7,550 shares of Turn Therapeutics common stock directly.
• The transaction was made pursuant to a contract, instruction, or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The purchase of company stock by a high-ranking executive like the Interim CFO is generally a positive indicator, signaling management's confidence in the company's future. The Rule 10b5-1 plan further suggests a considered, long-term view.

Positives

• An insider, specifically the Interim CFO, purchasing company stock signals confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-planned purchase rather than a reaction to immediate news, which can suggest a long-term positive outlook.

Future Outlook

The purchase by a key executive, made under a Rule 10b5-1 plan, suggests a positive long-term outlook from management regarding the company's value and future performance.

Management Comments

• The Reporting Person undertakes to provide to Turn Therapeutics Inc., any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Industry Context

Insider buying, particularly by a CFO, is often viewed by the market as a positive signal, indicating that those closest to the company believe its stock is undervalued or has strong growth potential, potentially outperforming peers.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the insider purchase as a positive signal of management confidence, potentially influencing investor sentiment and stock price.
• Employees: Could interpret the CFO's investment as a sign of stability and belief in the company's future.

Key Dates

Recommendation

The purchase of shares by the Interim CFO is a positive signal, indicating management's confidence in Turn Therapeutics' valuation and future prospects. While a single insider purchase may not warrant an immediate 'buy' recommendation, it strengthens the case for holding the stock, as it suggests internal belief in the company's long-term value.

Keywords

TTRX, Turn Therapeutics, Insider Trading, Form 4, Stock Purchase, CFO, Zuraiz Chaudhary, Rule 10b5-1